**Title:** Breakthrough in Lipoprotein(a) Treatment: Phase 3 Trials Underway
**Meta Description:** Eli Lilly and Amgen are advancing treatments for lipoprotein(a), a genetic cholesterol risk factor, with promising Phase 3 trials underway.
**URL Slug:** breakthrough-lipoprotein-a-treatment-phase-3-trials
**Headline:** Promising Advances in Lipoprotein(a) Treatments: Phase 3 Trials by Lilly and Amgen
Eli Lilly and Amgen are making significant strides in the treatment of lipoprotein(a), a genetic cholesterol variant that poses a heightened risk for heart attacks and strokes. Approximately 25% of individuals are affected by this condition, which is resistant to traditional statin therapies. Recently, Lilly announced that its experimental drug, lepodisiran, has shown remarkable efficacy, reducing lipoprotein(a) levels by 94% for six months after just one injection. The company is currently enrolling patients for a Phase 3 trial to further evaluate this promising treatment.
Meanwhile, Amgen has completed patient recruitment for its own Phase 3 study of olpasiran, a competing treatment that also targets lipoprotein(a). Although olpasiran is similarly effective, it may not have the same duration of action as lepodisiran. Additionally, Novartis is in the race with its Phase 3 trial of pelacarsen, a monthly injection that could yield results later this year.
These pharmaceutical companies are addressing a critical health issue, as high levels of lipoprotein(a) are a significant risk factor for cardiovascular disease, distinct from the cholesterol typically managed by statins. With an estimated one to two billion people globally affected by elevated lipoprotein(a), the potential market for effective treatments is substantial.
Lipoprotein(a) levels, along with C-reactive protein and LDL cholesterol, are key indicators of cardiovascular risk. While lifestyle changes and statins can effectively lower LDL cholesterol, lipoprotein(a) levels are primarily determined by genetics, making them less responsive to lifestyle modifications or existing medications. Individuals with this genetic disorder face a two to three times greater risk of heart attack.
The development of these innovative treatments has involved collaborations between major pharmaceutical companies and specialized biotech firms. Novartis is partnering with Ionis Pharmaceuticals, Amgen has teamed up with Arrowhead Pharmaceuticals, and Lilly is collaborating with Dicerna Pharmaceuticals, which was acquired by Novo Nordisk in 2021. Silence Therapeutics is independently developing its own lipoprotein(a) treatment.
All these therapies function by inhibiting the RNA messages that instruct liver cells to produce lipoprotein(a). Novartis and Ionis’s approach involves binding to RNA, while the other companies utilize small interfering RNA (siRNA) molecules that degrade the RNA, resulting in prolonged effects.
In Lilly’s recent Phase 2 trial, the significant reduction in lipoprotein(a) levels highlights the potential of these treatments to transform cardiovascular risk management. As these Phase 3 trials progress, the medical community eagerly anticipates the outcomes that could pave the way for new standards in treating this challenging cholesterol variant.
**FAQ Section:**
**Q: What is lipoprotein(a) and why is it significant?**
A: Lipoprotein(a) is a genetic variant of cholesterol that increases the risk of heart attacks and strokes. Unlike LDL cholesterol, it is not effectively treated with statins, making new therapies crucial for those affected.
